COMP <GO>
BMRN vs UNH // OPERATING MARGIN
BioMarin Pharmaceutical Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: BMRN 7
— UNH 7
▲ OPERATING MARGIN LEADER: BMRN
LAST: $57.44 (-1.83%) • MKT CAP: $11.33B
operating-margins
12.70%
LAST: $400.44 (-1.60%) • MKT CAP: $365.29B
operating-margins
4.82%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMRN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMRN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.70% | 88.57% | -10.87 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | 11.47% | -5.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 16.5x | +4.52 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 6.51% | 6.47% | +0.04 | BMRN | /fcf-yield <GO> |
| Operating Margin ACTIVE | 12.70% | 4.82% | +7.88 | BMRN | /operating-margins <GO> |
| Net Profit Margin | 10.80% | 3.14% | +7.66 | BMRN | /net-margins <GO> |
| Revenue Growth (YoY) | 12.90% | 6.46% | +6.44 | BMRN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.32% | -2.32 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.57 | 3.12 | +2.45 | BMRN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | BMRN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.11% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.4 | 57.4 | -3.00 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.33 | +0.62 | BMRN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.8x | 17.7x | +9.06 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.33B | $365.29B | -$353.97B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMRN REV | UNH REV | BMRN GROSS % | UNH GROSS % | BMRN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.22B | $447.57B | 77.7% | 88.7% | $725.0M | $16.07B |
| FY 2024 | $2.85B | $400.28B | 79.7% | 88.3% | $487.4M | $20.70B |
| FY 2023 | $2.42B | $371.62B | — | 89.6% | $50.4M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMRN // BETA 0.95
UNH // BETA 0.33